lazertinib
European Commission Approves Rybrevant, Lazcluze in EGFR-Mutated NSCLC
Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
J&J's Rybrevant, Lazcluze Land First-Line FDA Approval for Treating EGFR-Mutant NSCLC
The combination treatment is approved for patients whose lung tumors harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations.
J&J Seeking Frontline Rybrevant-Lazertinib FDA Approval in EGFR-Mutated NSCLC
The application contains data from the Phase III MARIPOSA trial in which the dual anti-EGFR regimen improved outcomes versus AstraZeneca's Tagrisso.
Experts at ESMO said the MARIPOSA studies support Rybrevant combinations as potential options for NSCLC, but survival data and patient stratification are needed.